MaxCyte (LON:MXCT)

MaxCyte (LON:MXCT)

Share Price
187.50 p
0 (0.00 %)
Market Cap
£107.42 m
Proactive Investors - Run By Investors For Investors

MaxCyte RNS Release

Webinar: non-viral cell engineering

RNS Number : 5521H
MaxCyte, Inc.
16 November 2018




MaxCyte, Inc.

("MaxCyte" or the "Company")


MaxCyte to host webinar:

"Non-viral cell engineering: enabling a therapeutic revolution"             


Gaithersburg, Maryland - 16 November 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, will host a webinar, entitled "Non-viral cell engineering: enabling a therapeutic revolution," for investors and sell-side analysts between 15:00 - 16:00 GMT on Tuesday 20th November 2018.


MaxCyte has established itself as a world leader in non-viral cell engineering - offering a rapid, safe and clinically-focused means of delivering the next generation of cell-based therapies, which is underlined by the Company's recent commercial and research partnerships with leading biotech companies including Kite, a Gilead Company; CRISPR Therapeutics; and Precision BioSciences.


This webinar will showcase and explain how MaxCyte's technology enables its partners to unlock the potential of their cutting-edge product development programs by giving them the means to create drugs using gene-editing technology in the treatment of inherited genetic diseases and cancer without using viral-vectors, which can be complicated and expensive to manufacture.


"Recent years have seen the emergence of a remarkable new class of cell-based therapies targeting many indications - from ultra-rare diseases affecting a handful of patients to some of the most common forms of cancer," said Doug Doerfler, President & CEO of MaxCyte, Inc. "These therapies are made possible by the extraordinary vision of scientists and clinicians and by a common core capability, the ability to engineer cells for patients."


"MaxCyte is at the forefront of this revolution in therapeutics and brings a uniquely powerful, validated and differentiated approach to cell engineering that is enabling pioneers in the industry to develop these new treatments as well as powering MaxCyte's own therapeutic development programs," he added. 


MaxCyte's business model provides not only a stable and growing recurring revenue stream from its technology access fees and disposable sales but offers significant medium- and long-term upside from potential milestone- and sales-based payments from its partners' therapeutic development programs. This has been demonstrated in the licence agreements recently entered into with CRISPR Therapeutics and Precision Biosciences. Milestones for MaxCyte's clinical licenses are generally followed by sales-based payments as products using MaxCyte's technology progress to commercialization.


The webinar will be followed by a Q&A session.


Please contact [email protected] if you would like to attend. Log-in details and a detailed agenda for the webinar will be provided in advance of the event.


About MaxCyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology platform to enable its biopharmaceutical industry partners to advance the development of innovative, cutting-edge medicines, particularly in cell therapy, including the use of gene editing tools in the treatment of inherited genetic diseases and immuno-oncology approaches to treating cancer.  The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top ten global biopharmaceutical companies, and has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit




MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer


+1 301 944 1660


Nominated Adviser and Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

James Stearns



+44 (0)20 7886 2500

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Sukaina Virji


+44 (0)203 709 5700

[email protected]



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

MaxCyte Timeline

November 13 2018

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use